Johnson & Johnson’s Drug Combination Improves Progression-Free Survival in Lung Cancer Trial Against AstraZeneca’s Therapy

The Mariposa study showed that a combination of two Johnson & Johnson (J&J) drugs, Rybrevant, and lazertinib, was successful in improving progression-free survival in a common type of metastatic lung tumor, compared to AstraZeneca’s Tagrisso. These interim results have been closely monitored, as they may position J&J to compete with AstraZeneca in the cancer drug market. The study focuses on lung cancer driven by mutations in the EGFR gene and continues to study patient survival rates. J&J plans to present these results at an upcoming medical conference.

To read more, click here.